HEPATIQ is the first automated software to precisely quantitate liver function. Liver function can be reduced by infections, alcohol and fat buildup. The liver can generate new functioning nodules, and blood flow to the liver may also increase, hence mitigating some of the damage. Thus, measuring liver function is very important.
Other tests estimate the extent of fibrosis in the liver and do not quantitate function. A recent study of more than 800,000 individuals published in Gastroenterology showed that fibrosis scoring systems have modest predictive value. Patient outcomes are determined by residual liver function. This was established in the 8 year, prospective, multi-center, NIH sponsored HALT-C trial, which concluded that quantitative liver function may be more accurate than staging fibrosis in predicting clinical outcomes.
HEPATIQ is cleared by the FDA. The test is simple, takes less than an hour and is reimbursed under CPT 78803. The patient is injected with a standard Technicium-99m sulfur colloid solution and imaged using SPECT. The images are analyzed by the HEPATIQ software and a report prepared for the physician. More information at www.hepatiq.com.